[{"id":"f07104db-d6a9-438c-a618-ef3832fea178","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652920","created_at":"2022-12-15T14:58:23.337Z","updated_at":"2024-07-02T16:35:11.688Z","phase":"Phase 1/2","brief_title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","source_id_and_acronym":"NCT05652920","lead_sponsor":"OriCell Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ori-C101"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-03"}]